L-DOPA (levodopa) modified composite medicine slow release stent coating and preparation method thereof

A drug and coating technology, applied in coatings, medical science, surgery, etc., can solve the problems of poor drug release kinetics, ineffective drug treatment, poor adhesion of metal substrates, etc., to achieve slow release and avoid Explosive release, good binding effect

Inactive Publication Date: 2010-10-20
FUZHOU UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the main problems of DESs are: first, the amount of drug loaded is insufficient to achieve the therapeutic effect; second, the drug release kinetics is not good, and the most common occurrence is burst release; third, drug den...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • L-DOPA (levodopa) modified composite medicine slow release stent coating and preparation method thereof
  • L-DOPA (levodopa) modified composite medicine slow release stent coating and preparation method thereof
  • L-DOPA (levodopa) modified composite medicine slow release stent coating and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] The present invention will be described in further detail through specific embodiments below in conjunction with the accompanying drawings, but the present invention is not limited to the following embodiments.

[0026] 1. Experimental part

[0027] 1.1 Raw material

[0028] Tetraethyl orthosilicate (TEOS), polyethylene glycol (PEG, molecular weight 6000), absolute ethanol (EtOH) and hydrochloric acid (HCl) were purchased from Sinopharm Group and were analytically pure. r-2aminopropyltriethoxysilane (APTES, 98%), levodopa (L-DOPA) and aspirin (ASA) were purchased from SigmaAldrich.

[0029] 1.2 Preparation of coating solution

[0030] At room temperature, measure 44.6mlTEOS, 21.6mlH 2 O. Mix and stir 70ml EtOH evenly, add HCl dropwise, adjust pH = 3, add 3.6g PEG6000 after magnetic stirring for 2 hours, continue stirring for 24 hours, slowly add APTES dropwise, adjust pH to neutral. Divide the prepared solution into two parts, marked as solution A and solution B res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Coating thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a preparation method of an L-DOPA (levodopa) modified organic-inorganic composite medicine slow release stent coating. The L-DOPA modified organic-inorganic composite medicine slow release stent coating is prepared by the steps of hydrolyzing tetraethyl orthosilicate which is a precursor liquid of SiO2, polycondensing and mixing with polyethylene glycol (PEG) and medicine, wherein L-DOPA is added to be used as a coating modifying agent and the coating is prepared by adopting a pull method. The coating can realize slow release of loaded medicine while ensuring better bonding with a metal stent, and effectively avoids burst release.

Description

technical field [0001] The invention relates to a coating material and a preparation process, in particular to an L-DOPA modified organic-inorganic composite drug slow-release stent coating and a preparation method thereof. Background technique [0002] Since the first successful introduction of stents by Sigwart et al. in 1987, postoperative assisted implantation of stents has become one of the most effective interventional methods. However, the trauma caused by the expansion of the balloon or the implantation of the stent itself during the treatment will cause the self-repair of the human body and produce a series of reactions leading to the occurrence of restenosis in the stent. The milestone progress in the treatment of in-stent restenosis is the use of drug-eluting stents (DrugElutingStents, DESs). DESs use the stent to load the drug and release it to the stenosis site, which can improve the efficacy of the drug while minimizing the side effects of the drug on normal o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/10A61L31/08A61L31/02A61L31/16
Inventor 詹红兵陈文平
Owner FUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap